Literature DB >> 26592521

Aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing NF-κB and NFATc1 activation and DC-STAMP expression.

Xiang-zhou Zeng1,2, Long-gang He1, Song Wang3, Keng Wang1, Yue-yang Zhang1, Lei Tao1, Xiao-juan Li1, Shu-wen Liu1.   

Abstract

AIM: Aconiti Lateralis Radix Preparata is a traditional Chinese medicine used to treat chronic arthritis and is highly effective against rheumatoid arthritis. However, the effects of aconine, a derivative of aconitum alkaloids, on osteoclasts, which can absorb bone, remain unknown. Here, we investigated the effects of aconine on osteoclast differentiation and bone resorption in vitro.
METHODS: The viability of mouse leukemic monocyte/macrophage cell line RAW264.7 was measured using CCK-8 assays. Osteoclast differentiation was induced by incubation of RAW264.7 cells in the presence of RANKL, and assessed with TRAP staining assay. Bone resorption was examined with bone resorption pits assay. The expression of relevant genes and proteins was analyzed using RT-PCR and Western blots. The activation of NF-κB and nuclear factor of activated T-cells (NFAT) was examined using stable NF-κB and NFATc1 luciferase reporter gene systems, RT-PCR and Western blot analysis.
RESULTS: Aconine (0.125, 0.25 μmol/L) did not affect the viability of RAW264.7 cells, but dose-dependently inhibited RANKL-induced osteoclast formation and bone resorptive activity. Furthermore, aconine dose-dependently inhibited the RANKL-induced activation of NF-κB and NFATc1 in RAW264.7 cells, and subsequently reduced the expression of osteoclast-specific genes (c-Src, β3-Integrin, cathepsin K and MMP-9) and the expression of dendritic cell-specific transmembrane protein (DC-STAMP), which played an important role in cell-cell fusion.
CONCLUSION: These findings suggest that aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing the activation of NF-κB and NFATc1 and the expression of the cell-cell fusion molecule DC-STAMP.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26592521      PMCID: PMC4753374          DOI: 10.1038/aps.2015.85

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  28 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

Review 2.  Therapeutic targeting of osteoclast function and pathways.

Authors:  Matthew L Broadhead; Jonathan C M Clark; Crispin R Dass; Peter F M Choong; Damian E Myers
Journal:  Expert Opin Ther Targets       Date:  2011-01-05       Impact factor: 6.902

Review 3.  Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis.

Authors:  Aline G Costa; Natalie E Cusano; Barbara C Silva; Serge Cremers; John P Bilezikian
Journal:  Nat Rev Rheumatol       Date:  2011-06-14       Impact factor: 20.543

4.  Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP).

Authors:  Ya-Hui Chiu; Kofi A Mensah; Edward M Schwarz; Yawen Ju; Masahiko Takahata; Changyong Feng; Loralee A McMahon; David G Hicks; Ben Panepento; Peter C Keng; Christopher T Ritchlin
Journal:  J Bone Miner Res       Date:  2012-01       Impact factor: 6.741

5.  Inhibitory effect of cantharidin on osteoclast differentiation and bone resorption.

Authors:  Myung Hee Kim; Ki Shuk Shim; Seong Hwan Kim
Journal:  Arch Pharm Res       Date:  2010-03-30       Impact factor: 4.946

6.  Lentivirus-mediated RNA interference of DC-STAMP expression inhibits the fusion and resorptive activity of human osteoclasts.

Authors:  Zhiyong Zeng; Chenqing Zhang; Junmin Chen
Journal:  J Bone Miner Metab       Date:  2013-03-24       Impact factor: 2.626

7.  Development and assessment of a complete-detoxication strategy for Fuzi (lateral root of Aconitum carmichaeli) and its application in rheumatoid arthritis therapy.

Authors:  Peijian Tong; Chengliang Wu; Xiaofen Wang; Hongzhou Hu; Hongting Jin; Changyu Li; Ying Zhu; Letian Shan; Luwei Xiao
Journal:  J Ethnopharmacol       Date:  2013-01-29       Impact factor: 4.360

8.  Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.

Authors:  Myung Hee Kim; Shi Yong Ryu; Joon Sig Choi; Yong Ki Min; Seong Hwan Kim
Journal:  J Cell Physiol       Date:  2009-12       Impact factor: 6.384

9.  Membrane-bound receptor activator of NFκB ligand (RANKL) activity displayed by osteoblasts is differentially regulated by osteolytic factors.

Authors:  Preetinder P Singh; A Gabrielle J van der Kraan; Jiake Xu; Matthew T Gillespie; Julian M W Quinn
Journal:  Biochem Biophys Res Commun       Date:  2012-04-27       Impact factor: 3.575

10.  Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 Pathways.

Authors:  Zhi-Feng Wei; Bei Tong; Yu-Feng Xia; Qian Lu; Gui-Xin Chou; Zheng-Tao Wang; Yue Dai
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

View more
  21 in total

1.  Adipocytes enhance expression of osteoclast adhesion-related molecules through the CXCL12/CXCR4 signalling pathway.

Authors:  Tingting Luo; Hongrui Liu; Wei Feng; Di Liu; Juan Du; Jing Sun; Wei Wang; Xiuchun Han; Jie Guo; Norio Amizuka; Xianqi Li; Minqi Li
Journal:  Cell Prolif       Date:  2016-11-21       Impact factor: 6.831

2.  A simple and robust reporter gene assay for measuring the bioactivity of anti-RANKL therapeutic antibodies.

Authors:  Chuanfei Yu; Lan Wang; Yongbo Ni; Junzhi Wang
Journal:  RSC Adv       Date:  2019-12-03       Impact factor: 4.036

3.  CS-semi5 Inhibits NF-κB Activation to Block Synovial Inflammation, Cartilage Loss and Bone Erosion Associated With Collagen-Induced Arthritis.

Authors:  Xiang Li; Xiaonan Tang; Yufei Wang; Changwei Chai; Zhehui Zhao; Haijing Zhang; Ying Peng; Lianqiu Wu
Journal:  Front Pharmacol       Date:  2021-07-09       Impact factor: 5.810

4.  LncRNA and mRNA profiling during activation of tilapia macrophages by HSP70 and Streptococcus agalactiae antigen.

Authors:  Honglin Luo; Huizan Yang; Yong Lin; Yongde Zhang; Chuanyan Pan; Pengfei Feng; Yanling Yu; Xiaohan Chen
Journal:  Oncotarget       Date:  2017-09-30

5.  Pu-erh Tea Extract Ameliorates Ovariectomy-Induced Osteoporosis in Rats and Suppresses Osteoclastogenesis In Vitro.

Authors:  Titi Liu; Shihua Ding; Dan Yin; Xiangdan Cuan; Chuanqi Xie; Huanhuan Xu; Xuanjun Wang; Jun Sheng
Journal:  Front Pharmacol       Date:  2017-05-31       Impact factor: 5.810

6.  TRPV2-induced Ca2+-calcineurin-NFAT signaling regulates differentiation of osteoclast in multiple myeloma.

Authors:  Hua Bai; Huayuan Zhu; Qing Yan; Xuxing Shen; Xiupan Lu; Juejin Wang; Jianyong Li; Lijuan Chen
Journal:  Cell Commun Signal       Date:  2018-10-16       Impact factor: 5.712

7.  Phenolic Compounds from the Rhizomes of Smilax china L. and Their Anti-Inflammatory Activity.

Authors:  Cheng Zhong; Deng Hu; Lian-Bing Hou; Lu-Yao Song; Ying-Jun Zhang; Yang Xie; Li-Wen Tian
Journal:  Molecules       Date:  2017-04-03       Impact factor: 4.411

8.  Osteoclastogenesis Behavior of Zirconia for Dental Implant.

Authors:  Boldbayar Ganbold; Seong-Kyun Kim; Seong-Joo Heo; Jai-Young Koak; Zang Hee Lee; Jaejin Cho
Journal:  Materials (Basel)       Date:  2019-03-04       Impact factor: 3.623

9.  Recombinant Human Endostatin Suppresses Mouse Osteoclast Formation by Inhibiting the NF-κB and MAPKs Signaling Pathways.

Authors:  Nong Chen; Ru-Feng Gao; Feng-Lai Yuan; Ming-Dong Zhao
Journal:  Front Pharmacol       Date:  2016-06-01       Impact factor: 5.810

Review 10.  Osteoclast Multinucleation: Review of Current Literature.

Authors:  Joe Kodama; Takashi Kaito
Journal:  Int J Mol Sci       Date:  2020-08-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.